Immunic (IMUX) Research & Development (2013 - 2026)

Immunic (IMUX) has 14 years of Research & Development data on file, last reported at $25.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 19.01% year-over-year to $25.6 million; the trailing twelve-month figure through Mar 2026 stood at $86.1 million (up 3.9% YoY), and the FY2025 full-year result was $82.0 million, up 2.42% from the prior year.
• Research & Development climbed to $25.6 million in Q1 2026, from $19.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $25.6 million in Q1 2026 to a low of $16.5 million in Q3 2022.
• A 5-year average of $20.1 million and a median of $20.0 million in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 51.45% in 2022 and fell 18.41% in 2024, its largest moves.
• Tracing IMUX's Research & Development over 5 years: stood at $20.7 million in 2022, then dropped by 7.0% to $19.3 million in 2023, then grew by 12.1% to $21.6 million in 2024, then dropped by 11.79% to $19.1 million in 2025, then soared by 34.39% to $25.6 million in 2026.
• Business Quant data shows IMUX's Research & Development at $25.6 million in Q1 2026, $19.1 million in Q4 2025, and $20.0 million in Q3 2025.